MX2020010444A - Complejos de péptidos bicíclicos en heterotándem. - Google Patents
Complejos de péptidos bicíclicos en heterotándem.Info
- Publication number
- MX2020010444A MX2020010444A MX2020010444A MX2020010444A MX2020010444A MX 2020010444 A MX2020010444 A MX 2020010444A MX 2020010444 A MX2020010444 A MX 2020010444A MX 2020010444 A MX2020010444 A MX 2020010444A MX 2020010444 A MX2020010444 A MX 2020010444A
- Authority
- MX
- Mexico
- Prior art keywords
- peptide complexes
- bicyclic peptide
- heterotandem bicyclic
- heterotandem
- binds
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 125000002619 bicyclic group Chemical group 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000003446 ligand Substances 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a complejos de péptido bicíclico en heterotándem que comprenden un primer ligando peptídico que se une a un componente presente sobre una célula inmunitaria, conjugado mediante un enlazador con un segundo ligando peptídico que se une a un componente presente sobre una célula de cáncer; la invención también se refiere al uso de dichos complejos de péptido bicíclico en heterotándem para prevenir, suprimir o tratar el cáncer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1805492.4A GB201805492D0 (en) | 2018-04-04 | 2018-04-04 | Heterotandem Bicyclic peptide complexes |
GBGB1820981.7A GB201820981D0 (en) | 2018-12-21 | 2018-12-21 | Heterotandem bicyclic peptide complexes |
PCT/GB2019/050951 WO2019193328A1 (en) | 2018-04-04 | 2019-04-02 | Heterotandem bicyclic peptide complexes |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020010444A true MX2020010444A (es) | 2021-01-08 |
Family
ID=66175434
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020010444A MX2020010444A (es) | 2018-04-04 | 2019-04-02 | Complejos de péptidos bicíclicos en heterotándem. |
Country Status (12)
Country | Link |
---|---|
US (2) | US11453703B2 (es) |
EP (1) | EP3774851A1 (es) |
JP (2) | JP2021520378A (es) |
KR (1) | KR20200139236A (es) |
CN (1) | CN112236442A (es) |
AU (1) | AU2019247795A1 (es) |
BR (1) | BR112020020349A2 (es) |
CA (1) | CA3095582A1 (es) |
IL (1) | IL277717A (es) |
MX (1) | MX2020010444A (es) |
SG (1) | SG11202009773VA (es) |
WO (1) | WO2019193328A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201607827D0 (en) | 2016-05-04 | 2016-06-15 | Bicycle Therapeutics Ltd | Bicyclic peptide-toxin conjugates specific for MT1-MMP |
EP3559018A1 (en) | 2016-12-23 | 2019-10-30 | Bicyclerd Limited | Peptide derivatives having novel linkage structures |
US10899798B2 (en) | 2017-06-26 | 2021-01-26 | Bicyclerd Limited | Bicyclic peptide ligands with detectable moieties and uses thereof |
JP2020529427A (ja) | 2017-08-04 | 2020-10-08 | バイスクルテクス・リミテッド | Cd137に対して特異的な二環式ペプチドリガンド |
GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
US10875894B2 (en) | 2018-02-23 | 2020-12-29 | Bicycletx Limited | Multimeric bicyclic peptide ligands |
US11180531B2 (en) * | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
CN113474045A (zh) * | 2018-12-21 | 2021-10-01 | 拜斯科技术开发有限公司 | Pd-l1特异性的双环肽配体 |
US20220088207A1 (en) * | 2018-12-21 | 2022-03-24 | Bicycletx Limited | Bicyclic peptide ligands specific for pd-l1 |
WO2020225577A1 (en) | 2019-05-09 | 2020-11-12 | Bicycletx Limited | Bicyclic peptide ligands specific for ox40 |
TW202110485A (zh) * | 2019-07-30 | 2021-03-16 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
WO2021028686A1 (en) * | 2019-08-13 | 2021-02-18 | Bicycletx Limited | Modified multimeric bicyclic peptide ligands |
EP4038096A1 (en) * | 2019-10-03 | 2022-08-10 | BicycleTX Limited | Heterotandem bicyclic peptide complexes |
GB201914872D0 (en) * | 2019-10-15 | 2019-11-27 | Bicycletx Ltd | Bicyclic peptide ligand drug conjugates |
KR20230074721A (ko) | 2020-08-17 | 2023-05-31 | 바이사이클티엑스 리미티드 | Nectin-4에 특이적인 이환 콘쥬게이트 및 이의 용도 |
GB202016331D0 (en) * | 2020-10-15 | 2020-12-02 | Bicyclerd Ltd | Bicyclic peptide ligand drug conjugates |
CA3206529A1 (en) * | 2021-01-08 | 2022-07-14 | Bicycletx Limited | Heterotandem bicyclic peptide complexes |
WO2022148979A1 (en) | 2021-01-11 | 2022-07-14 | Bicycletx Limited | Methods for treating cancer |
WO2022253051A1 (zh) * | 2021-06-01 | 2022-12-08 | 南京明德新药研发有限公司 | 多肽偶联药物及其应用 |
KR20240042656A (ko) * | 2021-08-17 | 2024-04-02 | 메드샤인 디스커버리 아이엔씨. | 신규구조를 갖는 폴리펩타이드 접합체 약물 및 그 응용 |
TWI803993B (zh) * | 2021-09-28 | 2023-06-01 | 廖嘉鴻 | 環胜肽自組裝3d微粒裝置及其製造方法 |
AU2022356942A1 (en) * | 2021-09-29 | 2024-05-09 | Conjustar (Zhuhai) Biologics Co., Ltd. | Tricyclic polypeptide conjugated drug and use thereof |
CN115819618B (zh) * | 2022-09-16 | 2023-10-27 | 哈尔滨工业大学 | 一种光激活的纳抗偶联物二聚化诱导剂pancid及其应用 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
WO2006078161A1 (en) | 2005-01-24 | 2006-07-27 | Pepscan Systems B.V. | Binding compounds, immunogenic compounds and peptidomimetics |
EP2257624B9 (en) | 2008-02-05 | 2012-08-01 | Medical Research Council | Methods and compositions |
GB0913775D0 (en) * | 2009-08-06 | 2009-09-16 | Medical Res Council | Multispecific peptides |
JP2013518807A (ja) * | 2010-02-04 | 2013-05-23 | メディカル リサーチ カウンシル | 多重特異性ペプチド |
WO2013050616A1 (en) * | 2011-10-07 | 2013-04-11 | Bicycle Therapeutics Limited | Modulation of structured polypeptide specificity |
US20140274759A1 (en) * | 2013-03-15 | 2014-09-18 | Bicycle Therapeutics Limited | Modification of polypeptides |
CA3220466A1 (en) * | 2014-10-29 | 2016-05-06 | Bicyclerd Limited | Bicyclic peptide ligands specific for mt1-mmp |
MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
RU2018139339A (ru) * | 2016-04-22 | 2020-05-22 | Эллигейтор Биосайенс Аб | Новые биспецифические полипептиды против cd137 |
JP2020529427A (ja) | 2017-08-04 | 2020-10-08 | バイスクルテクス・リミテッド | Cd137に対して特異的な二環式ペプチドリガンド |
GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
US10875894B2 (en) | 2018-02-23 | 2020-12-29 | Bicycletx Limited | Multimeric bicyclic peptide ligands |
GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
WO2020201753A1 (en) | 2019-04-02 | 2020-10-08 | Bicycletx Limited | Bicycle toxin conjugates and uses thereof |
TW202110485A (zh) | 2019-07-30 | 2021-03-16 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
EP4038096A1 (en) | 2019-10-03 | 2022-08-10 | BicycleTX Limited | Heterotandem bicyclic peptide complexes |
CA3158741A1 (en) | 2019-11-27 | 2021-06-03 | Gavin Bennett | Bicyclic peptide ligands specific for epha2 and uses thereof |
-
2019
- 2019-04-02 WO PCT/GB2019/050951 patent/WO2019193328A1/en unknown
- 2019-04-02 CA CA3095582A patent/CA3095582A1/en active Pending
- 2019-04-02 US US16/372,692 patent/US11453703B2/en active Active
- 2019-04-02 SG SG11202009773VA patent/SG11202009773VA/en unknown
- 2019-04-02 CN CN201980037963.XA patent/CN112236442A/zh active Pending
- 2019-04-02 EP EP19717554.0A patent/EP3774851A1/en active Pending
- 2019-04-02 KR KR1020207031802A patent/KR20200139236A/ko unknown
- 2019-04-02 BR BR112020020349-1A patent/BR112020020349A2/pt unknown
- 2019-04-02 JP JP2020554265A patent/JP2021520378A/ja active Pending
- 2019-04-02 MX MX2020010444A patent/MX2020010444A/es unknown
- 2019-04-02 AU AU2019247795A patent/AU2019247795A1/en active Pending
-
2020
- 2020-10-01 IL IL277717A patent/IL277717A/en unknown
-
2022
- 2022-05-12 US US17/663,169 patent/US20230008076A1/en active Pending
-
2024
- 2024-02-05 JP JP2024015762A patent/JP2024062998A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2021520378A (ja) | 2021-08-19 |
KR20200139236A (ko) | 2020-12-11 |
JP2024062998A (ja) | 2024-05-10 |
WO2019193328A1 (en) | 2019-10-10 |
US20190307836A1 (en) | 2019-10-10 |
IL277717A (en) | 2020-11-30 |
CN112236442A (zh) | 2021-01-15 |
SG11202009773VA (en) | 2020-10-29 |
EP3774851A1 (en) | 2021-02-17 |
BR112020020349A2 (pt) | 2021-01-05 |
US11453703B2 (en) | 2022-09-27 |
US20230008076A1 (en) | 2023-01-12 |
US20210299210A2 (en) | 2021-09-30 |
CA3095582A1 (en) | 2019-10-10 |
AU2019247795A1 (en) | 2020-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020010444A (es) | Complejos de péptidos bicíclicos en heterotándem. | |
MX2022001290A (es) | Complejos de peptido biciclico en heterotandem. | |
PH12019502875A1 (en) | Antibody molecules to cd73 and uses thereof | |
NZ753515A (en) | Methods for treatment of cancer comprising tigit-binding agents | |
PH12019500270A1 (en) | Combination therapy for cancer | |
NZ738008A (en) | Tigit-binding agents and uses thereof | |
MX2022011818A (es) | Metodos y composiciones para el direccionamiento de canceres de celulas t. | |
SA518400222B1 (ar) | أجسام مضادة لـ وتركيبات tim-3 | |
PH12016501411B1 (en) | Bifunctional cytotoxic agents | |
MY192822A (en) | An anti-ctla4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition and use | |
MX2019001517A (es) | Complejos de nanopartículas de albúmina modificada con anticuerpos para el tratamiento del cáncer. | |
MX2016006726A (es) | Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer. | |
WO2017136659A3 (en) | Humanized anti-cd3 antibodies, conjugates and uses thereof | |
MX2021007274A (es) | Molecula bifuncional anti-pd-1/sirpa. | |
MX2023008168A (es) | Complejos peptidicos biciclicos heterotandem. | |
MX2023007809A (es) | Compuestos de complejo de hierro para uso terapeutico. | |
PH12019550233A1 (en) | A novel anti-c-met antibody and use thereof | |
EA201992315A1 (ru) | Композиции и способы для лечения рака легкого | |
WO2019168897A3 (en) | Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents | |
MX2021000304A (es) | Terapias combinadas dirigidas a cd38 y tgf-beta. | |
EA202092388A1 (ru) | Гетеротандемные бициклические пептидные комплексы | |
WO2018146390A8 (fr) | Utilisation d'un compose appartenant a la famille des diuretiques pour traiter le cancer | |
MX2019007376A (es) | Anticuerpos contra el lif y usos de los mismos. | |
MX2020013923A (es) | Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos. | |
MX2019013019A (es) | USO DE 3,16-DIACETADO DE 26-AZIDO-22-OXOCOLEST-5-3ß, 16ß-DIILO COMO AGENTE ANTICANCERIGENO. |